Developer docs
API playgroundTry for free, no card

Search company profiles

DCPrime

Full company profile

uuid0003fnf

Namestring
DCPrime
Websiteurl
dcprime.nl
Company typeenum
Private
Founded yearint
2006
Descriptiontext

DCPrime is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Leiden, the Netherlands. The company develops novel cancer immunotherapies based on its proprietary DCOne platform technology, which is centered on dendritic cell-based approaches to oncology. Operating with a workforce of 11-50 employees, DCPrime is positioned in the European biotech ecosystem as a specialized developer of cell-based immuno-oncology therapeutics.

The company's core asset is the DCOne platform, the technical foundation for its pipeline of cancer immunotherapy candidates. As a clinical-stage developer, DCPrime's business model is built around advancing candidates through preclinical and clinical development, with the long-term value capture likely dependent on out-licensing, partnership milestone payments, or eventual commercialization of approved therapies. At present, there is no evidence of commercial product sales, recurring revenue, or named customers in the available data. Capital formation has come through a combination of venture rounds led by Van Herk Ventures, a SkylineDx co-investment, a Thuja Capital seed round, and a non-dilutive Horizon 2020 grant from the European Commission — total disclosed funding is approximately $26.5M, with the largest tranche of $18.7M raised in March 2018.

The company is led by a three-person executive team: Erik Manting as CEO, Ada Kruisbeek as Chief Scientific Officer, and Jeroen Rovers as Chief Medical Officer. This structure is consistent with a clinical-development-stage organization rather than a discovery-only operation. DCPrime's primary stakeholders at this stage are its investors, clinical investigators, and prospective pharma licensing partners rather than end patients or prescribing physicians, and its customer base in the traditional commercial sense does not yet exist.

Short descriptiontext

DCPrime is a clinical-stage biopharmaceutical company based in Leiden, Netherlands, developing novel cancer immunotherapies based on its proprietary DCOne dendritic cell platform technology.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLeiden, Netherlands
HQ citystring
Leiden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
cancer immunotherapy, dendritic cell therapy, biopharmaceutical development, oncology therapeutics, clinical stage biotech
Industry1 code
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

DCPrime is a clinical-stage biopharmaceutical company that develops novel cancer immunotherapies built on its proprietary DCOne platform technology. The company focuses on dendritic cell-based therapeutic approaches aimed at treating cancer, with drug candidates progressing through clinical trials.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1DCOne Platform-Based Cancer Immunotherapies
CategoryOncology Biopharmaceuticals
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DCPrime

Cancer Immunotherapydcprime.nl

DCPrime is a clinical-stage biopharmaceutical company based in Leiden, Netherlands, developing novel cancer immunotherapies based on its proprietary DCOne dendritic cell platform technology.

What DCPrime does

DCPrime is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Leiden, the Netherlands. The company develops novel cancer immunotherapies based on its proprietary DCOne platform technology, which is centered on dendritic cell-based approaches to oncology. Operating with a workforce of 11-50 employees, DCPrime is positioned in the European biotech ecosystem as a specialized developer of cell-based immuno-oncology therapeutics.

The company's core asset is the DCOne platform, the technical foundation for its pipeline of cancer immunotherapy candidates. As a clinical-stage developer, DCPrime's business model is built around advancing candidates through preclinical and clinical development, with the long-term value capture likely dependent on out-licensing, partnership milestone payments, or eventual commercialization of approved therapies. At present, there is no evidence of commercial product sales, recurring revenue, or named customers in the available data. Capital formation has come through a combination of venture rounds led by Van Herk Ventures, a SkylineDx co-investment, a Thuja Capital seed round, and a non-dilutive Horizon 2020 grant from the European Commission — total disclosed funding is approximately $26.5M, with the largest tranche of $18.7M raised in March 2018.

The company is led by a three-person executive team: Erik Manting as CEO, Ada Kruisbeek as Chief Scientific Officer, and Jeroen Rovers as Chief Medical Officer. This structure is consistent with a clinical-development-stage organization rather than a discovery-only operation. DCPrime's primary stakeholders at this stage are its investors, clinical investigators, and prospective pharma licensing partners rather than end patients or prescribing physicians, and its customer base in the traditional commercial sense does not yet exist.

DCPrime firmographics

Firmographics
Name
DCPrime
Website
https://dcprime.nl
Company type
Private
Founded year
2006
Headcount range
11–50 employees
Short description
DCPrime is a clinical-stage biopharmaceutical company based in Leiden, Netherlands, developing novel cancer immunotherapies based on its proprietary DCOne dendritic cell platform technology.
Ownership category
akta.pro rank

DCPrime industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cancer immunotherapy
  • Dendritic cell therapy
  • Biopharmaceutical development
  • Oncology therapeutics
  • Clinical stage biotech

Where DCPrime is headquartered

Location

Headquarters

HQ city
Leiden
HQ country
Netherlands
HQ region
Europe

Markets served

DCPrime business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

DCPrime product offering

Product offering

Core offering

DCPrime is a clinical-stage biopharmaceutical company that develops novel cancer immunotherapies built on its proprietary DCOne platform technology. The company focuses on dendritic cell-based therapeutic approaches aimed at treating cancer, with drug candidates progressing through clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • DCOne Platform-Based Cancer Immunotherapies

Companies that use DCPrime

Customer profile

Ideal customer profiles1 record

DCPrime technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

DCPrime partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights3 records

DCPrime competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks4 records

Key highlights6 records

Customer concentration

DCPrime social profiles

Digital presence

DCPrime financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DCPrime leadership team

Management profile

Number of profiles

Profiles3 records

DCPrime funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DCPrime M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DCPrime

What does DCPrime do?

DCPrime is a clinical-stage biopharmaceutical company that develops novel cancer immunotherapies built on its proprietary DCOne platform technology. The company focuses on dendritic cell-based therapeutic approaches aimed at treating cancer, with drug candidates progressing through clinical trials.

When was DCPrime founded?

DCPrime was founded in 2006. It employs 11 to 50 people.

Where is DCPrime based?

DCPrime is headquartered in Leiden, Netherlands, in the Europe region.

Does DCPrime have an API?

No public API is recorded for DCPrime.

What industry is DCPrime in?

DCPrime's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAF, Dendritic Cell & Other APC-based Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comBioStock Studio: Immunicum and DCprime enter immuno-oncology mergerSwedish Immunicum agreed to acquire all of DCprime's shares from Van Herk Investments, a Dutch clinical-stage cancer relapse vaccine company. The merger aims to establish global leadership in cell-based cancer immunotherapies. The deal was announced last week.news.cision.comCederquist represents DCprime in relation to its combination with ImmunicumCederquist represented DCprime in its combination with Immunicum AB, where Immunicum acquires all DCprime shares via share issuance to DCprime's majority shareholder Van Herk. The team includes Jonas Forsén, Fredrik Lundén, Wilhelm Lüning, Filip Gyulai, and Jessica Malhotra.GlobeNewswireDCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody PlatformsDCprime and Glycotope expanded their partnership with a licensing agreement to advance a program combining DCprime's DCOne relapse vaccine and Glycotope's anti-tumor antibody platform. The selected antibody program will be evaluated in preclinical studies for solid tumors. The companies aim to develop novel combination therapies for oncology.GlobeNewswirePCI Biotech announce a research collaboration with DCprime to explore novel cancer vaccination conceptsPCI Biotech and DCprime announced a research collaboration to develop novel cancer vaccination concepts based on tumour-independent antigens. The partnership combines PCI's photochemical internalisation technology with DCprime's relapse vaccine expertise. No further details were disclosed in the announcement.